Boston Scientific is set to acquire Penumbra for $14.5bn, expanding its vascular care offerings. Penumbra’s Lightning Bolt and Lightning Flash CAVT systems received FDA clearance in 2023 and 2024, adding to Boston’s peripheral intervention business. The acquisition is expected to close in 2026, driving growth in the global peripheral vascular devices market.

In Q3 2025, Boston reported a 16.7% increase in peripheral intervention business revenue to $702m. The deal with Penumbra will position Boston as a key player in the peripheral thrombectomy market, competing directly with Stryker. The acquisition will also boost Boston’s presence in vascular embolisation and aspiration thrombectomy for neurovascular devices.

GlobalData analysis projects the global peripheral vascular devices market to reach $21.45bn by 2034. Boston’s CEO, Mike Mahoney, anticipates the acquisition of Penumbra to enhance revenue and margins over time. The move aligns with industry trends of consolidating high-growth procedural segments, meeting the increasing clinical demand for integrated, workflow-efficient offerings.

Read more at Yahoo Finance: Boston Scientific acquires Penumbra in $14.5bn deal